These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27746785)

  • 1. HA Antibody-Mediated FcγRIIIa Activity Is Both Dependent on FcR Engagement and Interactions between HA and Sialic Acids.
    Cox F; Kwaks T; Brandenburg B; Koldijk MH; Klaren V; Smal B; Korse HJ; Geelen E; Tettero L; Zuijdgeest D; Stoop EJ; Saeland E; Vogels R; Friesen RH; Koudstaal W; Goudsmit J
    Front Immunol; 2016; 7():399. PubMed ID: 27746785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Divergent Requirement of Fc-Fcγ Receptor Interactions for
    Wang S; Ren H; Jiang W; Chen H; Hu H; Chen Z; Zhou P
    J Virol; 2017 Jun; 91(11):. PubMed ID: 28331095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact.
    Leon PE; He W; Mullarkey CE; Bailey MJ; Miller MS; Krammer F; Palese P; Tan GS
    Proc Natl Acad Sci U S A; 2016 Oct; 113(40):E5944-E5951. PubMed ID: 27647907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection.
    DiLillo DJ; Palese P; Wilson PC; Ravetch JV
    J Clin Invest; 2016 Feb; 126(2):605-10. PubMed ID: 26731473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner.
    Mullarkey CE; Bailey MJ; Golubeva DA; Tan GS; Nachbagauer R; He W; Novakowski KE; Bowdish DM; Miller MS; Palese P
    mBio; 2016 Oct; 7(5):. PubMed ID: 27703076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of GASDALIE Fc bound to the activating Fc receptor FcγRIIIa.
    Ahmed AA; Keremane SR; Vielmetter J; Bjorkman PJ
    J Struct Biol; 2016 Apr; 194(1):78-89. PubMed ID: 26850169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.
    Jain A; Poonia B; So EC; Vyzasatya R; Burch EE; Olsen HS; Mérigeon EY; Block DS; Zhang X; Schulze DH; Hanna NN; Twadell WS; Yfantis HG; Chan SL; Cai L; Strome SE
    Eur J Cancer; 2013 Oct; 49(15):3344-52. PubMed ID: 23871153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV.
    Motsoeneng BM; Dhar N; Nunes MC; Krammer F; Madhi SA; Moore PL; Richardson SI
    Front Immunol; 2022; 13():873191. PubMed ID: 35514992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
    Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
    PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
    Thomann M; Schlothauer T; Dashivets T; Malik S; Avenal C; Bulau P; Rüger P; Reusch D
    PLoS One; 2015; 10(8):e0134949. PubMed ID: 26266936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered aglycosylated full-length IgG Fc variants exhibiting improved FcγRIIIa binding and tumor cell clearance.
    Jo M; Kwon HS; Lee KH; Lee JC; Jung ST
    MAbs; 2018; 10(2):278-289. PubMed ID: 29173039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
    Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
    Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells.
    Pandey JP; Namboodiri AM
    Oncoimmunology; 2014 Jan; 3(1):e27317. PubMed ID: 24701371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
    Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
    J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.
    Hezareh M; Hessell AJ; Jensen RC; van de Winkel JG; Parren PW
    J Virol; 2001 Dec; 75(24):12161-8. PubMed ID: 11711607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
    Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
    Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity.
    Masuda K; Kubota T; Kaneko E; Iida S; Wakitani M; Kobayashi-Natsume Y; Kubota A; Shitara K; Nakamura K
    Mol Immunol; 2007 May; 44(12):3122-31. PubMed ID: 17379311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA.
    Suzuki M; Yamanoi A; Machino Y; Kobayashi E; Fukuchi K; Tsukimoto M; Kojima S; Kohroki J; Akimoto K; Masuho Y
    Biochem Biophys Res Commun; 2013 Jul; 436(3):519-24. PubMed ID: 23764395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.